期刊
VACCINE
卷 29, 期 28, 页码 4556-4564出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.04.061
关键词
Tick-borne encephalitis; TBE; Flavivirus
资金
- Novartis Vaccines and Diagnostics
- Novartis
- Pfizer
- Baxter
- GlaxoSmithKline
- Sanofi
- Novartis Vaccines Hungary Ltd
- Merck Sharp & Dohme Ltd (MSD)
- Sanofi Pasteur
Tick-borne encephalitis (TBE) is a potentially life-threatening disease in humans and is caused by a flavivirus spread by infected ticks (Ixodes ricinus and Ixodes persulcatus). THE is endemic across much of Central and Eastern Europe and the incidence is increasing, with numbers estimated to be as many as 8755 cases per year. The reasons for this increase are multi-faceted and may involve improvements in diagnosis and reporting of THE cases, increases in recreational activities in areas inhabited by infected ticks and changes in climatic conditions affecting tick habitats. Vaccination is the most effective method of preventingTBE; following a successful nationwide vaccination campaign in Austria, the annual number of TBE cases fell to about 10% of those reported in the pre-vaccination era. This report describes the findings of a group of leading experts from six Central and Eastern European countries who convened to discuss TBE in their region during the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) Nice, France, 4-8 May 2010. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据